Remove Communication Remove Diabetes Remove Magazine
article thumbnail

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

The drugmaker’s flagship drug semaglutide, known under the brand names Wegovy and Ozempic for obesity and type 2 diabetes treatment respectively, targets the glucagon-like peptide-1 receptor (GLP-1R), a key component of the incretin system. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

SCHOTT Pharma invests in RTU cartridge capacity expansion

Pharmaceutical Technology

Find out more RTU cartridges are essential for storing glucagon-like peptide-1 drugs, biologics, insulin and hormone therapies used for treating diabetes, obesity and other immunological conditions. Can pharma tariffs “Make America Manufacture Again”? It will further extend the site’s manufacturing capabilities for high-value solutions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How the patient voice is becoming vital for drug approval

pharmaphorum

This article appears in our free digital magazine Deep Dive: Market Access 2021. This can lead to metabolic abnormalities including insulin resistance, diabetes, and elevated levels of blood lipids (such as high cholesterol). Read below for a preview! . Fighting for access.

article thumbnail

Genomics to roll out predictive clinical test across UK

Pharmaceutical Technology

The full UK test will also look at a person’s susceptibility to developing type 2 diabetes, prostate cancer and breast cancer. Can pharma tariffs “Make America Manufacture Again”? The test was also evaluated in a clinical trial conducted with the NHS to evaluate its ability to detect signs of cardiovascular disease.

article thumbnail

Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

Pharmaceutical Technology

Find out more Fleischer said that the programme will provide more services for patients receiving its glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide, which is marketed as Wegovy for weight loss and Ozempic in type 2 diabetes, including fitness and dietary advice. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Eylea is approved in four indications in Europe: the treatment of ‘wet’ age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

When Plaid effectively forced financial institutions to take an open-protocol approach to digital interoperability, “Every bank (took) their five-year strategy on digitizing and brought it down into one or two years,” CEO Zach Perret said in an interview with Fortune magazine. The time to cross that bridge has passed. About the author.

HIPAA 98